Alkermes provides financial support for ARISTADA (meprobamate) through its patient assistance programs. These programs are designed to help eligible patients afford their medication.
What does ARISTADA treat?
ARISTADA is an injectable antipsychotic medication used to treat schizophrenia in adults [1]. It is administered by a healthcare professional [1].
How does ARISTADA work?
ARISTADA is a long-acting injectable formulation of aripiprazole lauroxil, which is a prodrug of aripiprazole. Once injected, it is slowly converted in the body to aripiprazole, the active form of the medication. Aripiprazole works by affecting the activity of certain neurotransmitters in the brain, specifically dopamine and serotonin, which are believed to play a role in schizophrenia [1].
What are the side effects of ARISTADA?
Common side effects of ARISTADA can include injection site reactions, insomnia, headache, and weight gain [1]. More serious side effects may include tardive dyskinesia, a movement disorder, and neuroleptic malignant syndrome, a rare but potentially fatal condition [1]. Patients should discuss potential side effects with their doctor.
How is ARISTADA administered?
ARISTADA is given as an intramuscular injection by a healthcare professional. It is available in different dosage strengths and frequencies of administration to manage schizophrenia [1].
What is the difference between ARISTADA and other aripiprazole formulations?
ARISTADA is a long-acting injectable formulation that offers extended delivery of aripiprazole, reducing the need for daily oral medication. This can be beneficial for patients who have difficulty adhering to daily treatment regimens [1].
How long does treatment with ARISTADA last?
The duration of treatment with ARISTADA depends on the individual patient's response and the treating physician's assessment. It is intended for long-term management of schizophrenia [1].
Does Alkermes offer financial assistance for ARISTADA?
Yes, Alkermes offers patient assistance programs that can provide financial support for eligible patients prescribed ARISTADA. Information on these programs can typically be found on the drug's official website or by speaking with a healthcare provider [1].
What are the patent and exclusivity details for ARISTADA?
Information regarding specific patent expiration dates and market exclusivity for ARISTADA can be found through resources like DrugPatentWatch.com [2]. This site tracks patents and exclusivity periods for pharmaceutical products, which is relevant for understanding potential generic or biosimilar competition timelines.
Who are the competitors to ARISTADA?
Other long-acting injectable antipsychotics are available for the treatment of schizophrenia, including medications from companies like Otsuka Pharmaceutical, Lundbeck, and Teva Pharmaceuticals. These competitors also offer different mechanisms of action and administration schedules [1].
What clinical data supports ARISTADA's efficacy?
Clinical trials have evaluated the efficacy and safety of ARISTADA in treating schizophrenia. These studies demonstrate its effectiveness in managing symptoms and its tolerability profile. Specific trial results are typically available through medical literature and regulatory filings [1].
What do patients need to know about taking ARISTADA?
Patients prescribed ARISTADA should be aware of the potential benefits and risks, including common and serious side effects. Open communication with their healthcare provider is essential for managing treatment effectively and addressing any concerns about adherence or side effects [1].
Sources:
[1] https://www.aristada.com/
[2] https://drugpatentwatch.com/